Sino Biopharmaceutical dividend and valuation

1177 · HKEX · HKD

Compare Sino Biopharmaceutical
$5.11Change from previous close: −4.85%Absolute change: −$0.26

Close · November 20, 2026

Valuation

Sino Biopharmaceutical paid $0.12 per share in dividends over the last 12 months (yield 2.4%). Last ex-dividend date: September 1, 2026. The P/E ratio is 34.2. The average price target of 23 analysts is $8.49.

Data as of November 21, 2026

Sino Biopharmaceutical compared with similar companies

Sino Biopharmaceutical's P/E (trailing 12 months): 34.2, −7% against the median of a group of 8 similar companies (36.8).

Sino Biopharmaceutical's metrics compared with similar companies
MetricSino BiopharmaceuticalMedian25th–75th percentileBand
P/E (trailing 12 months)34.236.832.6 – 57.4Middle
Forward P/E15.831.722.2 – 41.7Low
EV/EBITDA9.4829.318.2 – 67.4Low
Price/book2.394.162.56 – 7.85Low
Price/sales2.719.885.78 – 31.6Low
Gross margin82.4%74.6%56.9% – 79.1%High
Operating margin28.2%21.1%10.7% – 32.0%Middle
Net margin7.1%11.1%7.2% – 26.8%Low
ROE14.1%10.4%5.0% – 19.8%Middle
Debt/equity0.370.110.05 – 0.38Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$91.32B
Enterprise value
$98.99B
PEG
0.68
EV/revenue
2.94

Profitability and growth

ROA
7.5%
ROIC
9.8%
Revenue growth (year over year)
10.6%
Earnings growth (year over year)
1.5%

Financial health

Total cash
$27.58B
Total debt
$17.17B
Current ratio
1.63
Quick ratio
1.43
Altman Z-Score
3.20
Piotroski F-Score
6.00

Dividends

Annual dividend per share
$0.12
Dividend yield
2.4%
Payout ratio
80.0%
Ex-dividend date
September 1, 2026

Analysts and estimates

Average price target
$8.49
Median price target
$8.71
High price target
$10.99
Low price target
$5.95
Analysts with a price target
23
Consensus
Strong buy
Forward EPS
$0.32
EPS estimate, current year
$0.26

Shares and trading

Beta
0.66
Average volume
80.03M
Shares outstanding
17.78B
Float
8.73B
Institutional ownership
23.1%
Insider ownership
48.7%